In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 101 to 150 of 342

Sort by

Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]	Technology appraisal guidance	TBC
Efgartigimod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy [ID6409]	Technology appraisal guidance	29 July 2026
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]	Technology appraisal guidance	TBC
Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over [TSID11847]	Technology appraisal guidance	TBC
Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]	Technology appraisal guidance	TBC
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]	Technology appraisal guidance	TBC
Eneboparatide for treating chronic hypoparathyroidism [ID6532]	Technology appraisal guidance	TBC
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]	Technology appraisal guidance	15 June 2022
Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6607]	Technology appraisal guidance	TBC
Ensitrelvir for treating COVID 19 [ID6231]	Technology appraisal guidance	TBC
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338]	Technology appraisal guidance	25 February 2026
Epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6586]	Technology appraisal guidance	3 September 2026
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]	Technology appraisal guidance	TBC
Etripamil for treating paroxysmal supraventricular tachycardia [ID6581]	Technology appraisal guidance	TBC
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920	Technology appraisal guidance	TBC
Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]	Technology appraisal guidance	TBC
Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]	Technology appraisal guidance	TBC
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]	Technology appraisal guidance	TBC
Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514]	Technology appraisal guidance	4 June 2026
Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]	Technology appraisal guidance	TBC
Ganaxolone for adjunctive treatment of epilepsy associated with tuberous sclerosis complex with CDKL5 deficiency disorder [TSID12126]	Technology appraisal guidance	TBC
Gefurulimab for treating antibody-positive generalised myasthenia gravis [TSID12256]	Technology appraisal guidance	TBC
Giredestrant with everolimus for treating oestrogen-receptor positive HER2-negative advanced breast cancer after cyclin-dependent kinase 4 and 6 inhibitor and endocrine treatment ID6576	Technology appraisal guidance	TBC
Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID5072]	Technology appraisal guidance	TBC
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312	Technology appraisal guidance	TBC
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]	Technology appraisal guidance	TBC
Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [ID6487]	Technology appraisal guidance	11 March 2026
Govorestat for treating classic galactosemia in people 2 to 65 years [TSID12071]	Technology appraisal guidance	TBC
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]	Technology appraisal guidance	22 April 2026
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]	Technology appraisal guidance	TBC
Ianalumab for treating active Sjogren's syndrome [ID6634]	Technology appraisal guidance	TBC
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]	Technology appraisal guidance	TBC
Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable ID6596	Technology appraisal guidance	TBC
Iclepertin for treating cognitive impairment associated with schizophrenia [ID6483]	Technology appraisal guidance	TBC
Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over ID6579	Technology appraisal guidance	TBC
ID6610 Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy (review of TA901)	Technology appraisal guidance	3 September 2026
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]	Technology appraisal guidance	TBC
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]	Technology appraisal guidance	10 September 2026
Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]	Technology appraisal guidance	12 June 2026
Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [ID6551]	Technology appraisal guidance	TBC
Inebilizumab for treating AQP4-IgG-seropositive neuromyelitis optica spectrum disorders [ID6430]	Technology appraisal guidance	TBC
Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]	Technology appraisal guidance	TBC
Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]	Technology appraisal guidance	25 February 2026
Insulin efsitora alfa for treating type 1 diabetes in people on multiple daily insulin injections [ID6498]	Technology appraisal guidance	TBC
Insulin efsitora alfa for treating type 2 diabetes ID6499	Technology appraisal guidance	22 October 2026
Insulin icodec for treating type 2 diabetes [ID6175]	Technology appraisal guidance	TBC
Intrathecal onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [ID6556]	Technology appraisal guidance	26 August 2026
Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]	Technology appraisal guidance	TBC
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]	Technology appraisal guidance	TBC
Ipatasertib with fulvestrant for treating oestrogen-receptor positive HER2-negative advanced breast cancer after CDK 4/6 and aromatase inhibitor treatment [ID12194]	Technology appraisal guidance	TBC

Results per page

10
25
50
All